Here we go boys-GERN read this news! (COMTEX) B: Financial Relations Inc: Geron Wins Stem Cell Technology Paten and HemoSense Signs Exclusive Distribution Agreement B: Financial Relations Inc: Geron Wins Stem Cell Technology Patent and HemoSense Signs Exclusive Distribution Agreement with Cardinal Health ( M2 PRESSWIRE )
Oct 06, 2004 (M2 PRESSWIRE via COMTEX) -- City of Industry, CA - HemoSense, Inc. recently announced the signing of an exclusive three-year agreement with Cardinal Health, Inc. (NYSE:CAH) to market, sell and distribute HemoSense's INRatio product line to health-care providers in the United States. Under the agreement, Cardinal Health will provide the INRatio product line to physician offices, clinics, surgery centers, and ambulatory centers within integrated delivery networks (IDNs). Financial terms were not disclosed. Geron Corporation (NASDAQ: GERN) announced today that it has been granted U.S. Patent No. 6,800,480, covering the growth of human embryonic stem cells (hESCs) in the absence of feeder cells. The technology covered by the new patent will greatly facilitate scalable commercial manufacture of hESC-based therapeutic products.
U.S. BioDefense, Inc. (OTCBB: UBDF) announced recently that the company had retained the business planning services of TriTech. TriTech is a Small Business Development Center centered on helping Southern California people with high-tech/high-growth business concepts learn how to bring their ideas to market. U.S. BioDefense also recently announced the Defense Logistics Agency partnership, a tier of the Department of Defense for the United States of America. Partners with a Central Contractor Registration number have exclusive access to contract with various US Government Agencies which in turn increases potential sales opportunities for U.S. BioDefense.
About Financial Relations, Inc.
Through a comprehensive financial communications program, we assist our client companies capitalize on greater exposure to Wall Street. They have experienced improved liquidity and increased trading volume to help improve capital access.
Regardless of a company`s size, age or track record, they can establish a broader, more diverse audience for their investment idea. Financial Relations, Inc. combines the most thorough combination of skills, strategies and superb execution vital to an aggressive and effective financial communications program. We put our vast expertise and resources to work for our clients - partnering to achieve tangible results and measurable success. Financial Relations, Inc. charges each client $10,000 in cash for news distribution may have an equity position of up to 4.9% in the companies mentioned herein and may buy or sell the stock any time. Please visit our Section 17B disclaimer at www.financialrelationsinc.com/disclaimer.html
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.